Search research articles
Contact Us
Filters
Showing results (61-70 of 513) with videos related to
Page
of 52
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 1, 2022
Continuation of Pembrolizumab with Additional Chemotherapy after Progression with PD-1/PD-L1 Inhibitor Monotherapy in Patients with Advanced NSCLC: A Randomized, Placebo-Controlled Phase II Study
Hyun Ae Jung, Sehhoon Park, Yoon-La Choi, et al.
Journal of Neurochemistry
|
September 25, 2014
Metabolomic comparison between cells over-expressing isocitrate dehydrogenase 1 and 2 mutants and the effects of an inhibitor on the metabolism
He Wen, Hye Rim Cho, Taeho Yun, et al.
Cancer Research and Treatment
|
May 18, 2023
Phase II Trial of Combined Durvalumab Plus Tremelimumab with Proton Therapy for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
Hana Kim, Sehhoon Park, Hyun Ae Jung, et al.
BMC Cancer
|
October 22, 2025
Combination of chemotherapy and immune checkpoint inhibitors in non-small cell lung cancer with actionable gene alterations other than EGFR, ALK, and ROS1 mutations: a retrospective observational study
Ji Eun Shin, Sehhoon Park, Hyun Ae Jung, et al.
BMC Cancer
|
August 8, 2020
Clinical outcomes of immune checkpoint inhibitors for patients with recurrent or metastatic head and neck cancer: real-world data in Korea
Hyera Kim, Minsuk Kwon, Binnari Kim, et al.
Journal of Vascular and Interventional Radiology : JVIR
|
April 23, 2013
Survival outcomes and prognostic factors of transcatheter arterial chemoembolization for hepatic neuroendocrine metastases
Saebeom Hur, Jin Wook Chung, Hyo-Cheol Kim, et al.
Translational Lung Cancer Research
|
November 19, 2020
The different central nervous system efficacy among gefitinib, erlotinib and afatinib in patients with epidermal growth factor receptor mutation-positive non-small cell lung cancer
Hyun Ae Jung, Sook Young Woo, Se-Hoon Lee, et al.
Journal of Cancer Research and Clinical Oncology
|
March 23, 2019
Impact of EGFR mutation on the clinical efficacy of PD-1 inhibitors in patients with pulmonary adenocarcinoma
Jang Ho Cho, Hyun Ae Jung, Se-Hoon Lee, et al.
Translational Lung Cancer Research
|
January 11, 2024
Effectiveness and safety of amivantamab in EGFR exon 20 insertion (E20I) mutations in non-small cell lung cancer (NSCLC)
Dae-Ho Choi, Hyun Ae Jung, Sehhoon Park, et al.
Plos One
|
September 19, 2024
Repeated rebiopsy for detection of EGFR T790M mutation in patients with advanced-stage lung adenocarcinoma: Associated factors and treatment outcomes of Osimertinib
Taeyun Kim, Junsu Choe, Sun Hye Shin, et al.
Page
of 52
Search research articles
Search
Showing results (61-70 of 513) with videos related to
Sort By:
Page
of 52
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 1, 2022
Continuation of Pembrolizumab with Additional Chemotherapy after Progression with PD-1/PD-L1 Inhibitor Monotherapy in Patients with Advanced NSCLC: A Randomized, Placebo-Controlled Phase II Study
Hyun Ae Jung, Sehhoon Park, Yoon-La Choi, et al.
Journal of Neurochemistry
|
September 25, 2014
Metabolomic comparison between cells over-expressing isocitrate dehydrogenase 1 and 2 mutants and the effects of an inhibitor on the metabolism
He Wen, Hye Rim Cho, Taeho Yun, et al.
Cancer Research and Treatment
|
May 18, 2023
Phase II Trial of Combined Durvalumab Plus Tremelimumab with Proton Therapy for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
Hana Kim, Sehhoon Park, Hyun Ae Jung, et al.
BMC Cancer
|
October 22, 2025
Combination of chemotherapy and immune checkpoint inhibitors in non-small cell lung cancer with actionable gene alterations other than EGFR, ALK, and ROS1 mutations: a retrospective observational study
Ji Eun Shin, Sehhoon Park, Hyun Ae Jung, et al.
BMC Cancer
|
August 8, 2020
Clinical outcomes of immune checkpoint inhibitors for patients with recurrent or metastatic head and neck cancer: real-world data in Korea
Hyera Kim, Minsuk Kwon, Binnari Kim, et al.
Journal of Vascular and Interventional Radiology : JVIR
|
April 23, 2013
Survival outcomes and prognostic factors of transcatheter arterial chemoembolization for hepatic neuroendocrine metastases
Saebeom Hur, Jin Wook Chung, Hyo-Cheol Kim, et al.
Translational Lung Cancer Research
|
November 19, 2020
The different central nervous system efficacy among gefitinib, erlotinib and afatinib in patients with epidermal growth factor receptor mutation-positive non-small cell lung cancer
Hyun Ae Jung, Sook Young Woo, Se-Hoon Lee, et al.
Journal of Cancer Research and Clinical Oncology
|
March 23, 2019
Impact of EGFR mutation on the clinical efficacy of PD-1 inhibitors in patients with pulmonary adenocarcinoma
Jang Ho Cho, Hyun Ae Jung, Se-Hoon Lee, et al.
Translational Lung Cancer Research
|
January 11, 2024
Effectiveness and safety of amivantamab in EGFR exon 20 insertion (E20I) mutations in non-small cell lung cancer (NSCLC)
Dae-Ho Choi, Hyun Ae Jung, Sehhoon Park, et al.
Plos One
|
September 19, 2024
Repeated rebiopsy for detection of EGFR T790M mutation in patients with advanced-stage lung adenocarcinoma: Associated factors and treatment outcomes of Osimertinib
Taeyun Kim, Junsu Choe, Sun Hye Shin, et al.
Page
of 52